Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab monotherapy after prior anti-CTLA-4 treatment in advanced melanoma
NL-OMON47051Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in melanoma, sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of grade 3 or higher treatment-related select adverse events. Started Mar 2015; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON47051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47051.